Get the Daily Brief
Latest Biotech News
Wegovy pill lands in US — pricing, employer coverage headaches loom
Novo Nordisk launched the oral formulation of Wegovy in the U.S., listing insured patient copays as low as $25 per month and a $149 cash price. The company positioned the pill to broaden access to...
Setrusumab fails Phase III fracture endpoints — Ultragenyx and Mereo plan cuts
Ultragenyx and Mereo reported that setrusumab, an anti‑sclerostin antibody for osteogenesis imperfecta, missed primary fracture‑rate endpoints in the Phase III portions of the Orbit and Cosmic...
Novo Nordisk launches Wegovy pill: $25 insured, $149 cash
Novo Nordisk launched an oral formulation of its obesity drug Wegovy in the US, setting insured patient co-pay as low as $25 per month and a $149 cash price. The company disclosed the pricing...
Setrusumab misses primary endpoints: Ultragenyx, Mereo to cut costs
Ultragenyx and Mereo said setrusumab failed to meet primary endpoints in two late‑phase trials for brittle bone disease (osteogenesis imperfecta), missing statistically significant reductions in...
St. Jude publishes assay to detect base-editor off-targets – improves safety screening
St. Jude Children’s Research Hospital released a new method to detect small off‑target genome changes from base editors, the team said. The approach aims to make precision genome‑editing safety...
Optimized AAV9 improves safety, efficacy in SMARD1 models
Researchers reported optimization efforts for AAV9‑based gene therapy targeting SMARD1 (spinal muscular atrophy with respiratory distress 1) and related CMT2S models, detailing adjustments that...
11‑amino‑acid peptide thwarts CRC immune evasion: Cell Research
A study published in Cell Research described an engineered 11‑amino‑acid peptide that targets PTPN13 and the C‑terminal region of APC to block colorectal cancer (CRC) mechanisms that enable immune...
Romosozumab outperforms PTH analogs — fracture reduction evidence mounts
Two recent reports compared romosozumab, an anti‑sclerostin monoclonal antibody, with parathyroid hormone (PTH 1–34) analogs for preventing osteoporotic fractures in women. Authors found...
Live tumor fragment platform predicts immunotherapy response — translational tool
Researchers unveiled a live tumor fragment platform that preserves tumor architecture and immune components ex vivo to test immunotherapy responses across multiple agents. The system enables...
Liquid biopsy collaboration maps MASH biology — Hepta leads effort
Hepta announced a collaboration to map the biology of metabolic dysfunction‑associated steatohepatitis (MASH) using a novel liquid biopsy platform designed to capture multiomic signals from blood....
Serum biomarkers track MIS‑C severity and recovery: Pediatric Research
A Pediatric Research study identified serum immune biomarkers that correlate with severity and clinical recovery in multisystem inflammatory syndrome in children (MIS‑C). Investigators measured...
High‑CD14 urothelial cells drive neutrophil‑rich microenvironment after radiation
A study by Chiang et al. reported that urothelial cancers with high CD14 expression sculpt a neutrophil‑rich tumor microenvironment following radiation, which can blunt antitumor immunity and...
Setrusumab misses fracture endpoints – Ultragenyx, Mereo to cut costs
Ultragenyx and Mereo announced that setrusumab failed to meet primary fracture endpoints in two late-stage trials, prompting an immediate reassessment of operations and planned expense reductions....
St. Jude unveils method to detect base-editor off-targets – safety tool released
St. Jude Children's Research Hospital published a new method to more sensitively identify small off-target genome edits from base editors, enabling clearer safety assessments for precision genome...
AAV9 optimization advances for SMARD1 – efficiency and safety signals reported
Researchers reported optimized AAV9-based gene therapy strategies for SMARD1 (spinal muscular atrophy with respiratory distress type 1) that improve delivery and therapeutic indices in preclinical...
Tiny peptide reverses colorectal immune evasion – lipid signature fuels progression
Two independent studies revealed actionable mechanisms driving colorectal cancer immune escape and progression. A Cell Research report described an engineered 11–amino–acid peptide derived from...
Ex vivo tumor fragments and single-cell maps... new tools to test immunotherapies
Teams reported two complementary advances for evaluating cancer therapies ex vivo and in situ. A live tumor fragment platform enables functional testing of immunotherapies on intact tumor...
High‑CD14 urothelial cells recruit neutrophils after radiation – pro‑metastatic niche
Chiang et al. report that urothelial cancer cells with elevated CD14 expression reshape the tumor microenvironment into a neutrophil‑rich state following radiation. The study links tumor-intrinsic...
Psilocybin-assisted therapy shows early signal in binge‑eating pilot – small study
A pilot study led by Dr. Dallery tested psilocybin‑assisted therapy in patients with binge eating disorder (BED) and reported reductions in binge episodes and improvements in eating-related...
Serum biomarkers map MIS‑C severity and recovery – pediatric immune signatures
Wolff and Koutroulis published a Pediatric Research study identifying serum immune biomarkers that track severity and recovery in Multisystem Inflammatory Syndrome in Children (MIS‑C). The...